UTAH MEDICAL PRODUCTS, INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- UTAH MEDICAL PRODUCTS, INC. payments for repurchase of common stock for the quarter ending 2026-06-30 was $78.00K, a 97.76% decline year-over-year.
- UTAH MEDICAL PRODUCTS, INC. payments for repurchase of common stock for the quarter ending 2026-03-31 was $128.00K, a 96.03% decline year-over-year.
- UTAH MEDICAL PRODUCTS, INC. payments for repurchase of common stock for the quarter ending 2025-12-31 was $994.00K, a 85.18% decline year-over-year.
- UTAH MEDICAL PRODUCTS, INC. payments for repurchase of common stock for the quarter ending 2025-09-30 was $653.00K, a 83.11% decline year-over-year.
- UTAH MEDICAL PRODUCTS, INC. payments for repurchase of common stock for fiscal 2025 was $8.36M, a 58.16% decline from fiscal 2024.
- UTAH MEDICAL PRODUCTS, INC. payments for repurchase of common stock for fiscal 2024 was $19.97M.
- UTAH MEDICAL PRODUCTS, INC. payments for repurchase of common stock for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- UTAH MEDICAL PRODUCTS, INC. payments for repurchase of common stock for fiscal 2022 was $2.50M.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.85M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $128.00K 10-Q · filed 2026-05-12 | $5.26M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $994.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $8.36M 10-K · filed 2026-03-27 |
| 2025-09-30 | $653.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $14.07M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $3.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $17.28M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $3.22M 10-Q · filed 2026-05-12 | $20.20M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $6.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $19.97M 10-K · filed 2026-03-27 |
| 2024-09-30 | $3.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $13.26M derived: sum of 4 quarters · filed 2026-03-27 |
| 2024-06-30 | $6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $9.39M derived: sum of 4 quarters · filed 2026-03-27 |
| 2024-03-31 | $2.99M 10-Q · filed 2025-05-15 | $2.99M derived: sum of 4 quarters · filed 2026-03-27 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $0.00 10-K · filed 2026-03-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $2.50M 10-K · filed 2025-03-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $0.00 10-K · filed 2024-03-26 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$1.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $550.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-11 | $550.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | -$1.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-28 | $6.98M 10-K/A · filed 2023-03-28 |
| 2020-09-30 | $551.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $6.98M derived: sum of 4 quarters · filed 2022-03-25 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $6.43M derived: sum of 4 quarters · filed 2022-03-25 |
| 2020-03-31 | $6.43M 10-Q · filed 2021-05-11 | $6.82M derived: sum of 4 quarters · filed 2022-03-25 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-25 | $398.00K 10-K · filed 2022-03-25 |
| 2019-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2020-11-09 | |
| 2019-06-30 | $398.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-08 | |
| 2018-12-31 | $1.21M 10-K · filed 2021-03-26 | |
| 2017-12-31 | $0.00 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |